Long-term Outcome Evaluation of Patients Undergoing Autologous Chondrocyte Transplantation Delivered on Biomaterial

Launched by ISTITUTO ORTOPEDICO RIZZOLI · Jan 26, 2024

Keywords

ClinConnect Summary

The Chondro-Long study is looking at the long-term outcomes of a specific knee cartilage repair surgery called autologous chondrocyte transplantation, which was performed on patients between 1999 and 2006. This surgery is used to treat serious damage to the cartilage in the knee joint, specifically for conditions classified as Outerbridge grade III and IV. The goal of the study is to gather information over a period of up to 25 years to see how effective this treatment is in reducing pain and improving the ability to move and function in daily life.

To be eligible for this study, patients need to have had the surgery at the Rizzoli Orthopaedic Institute and be between 14 and 60 years old at that time. Both men and women can participate, but those who are no longer reachable for follow-up will not be included. Participants can expect to share their experiences and health status over the years as researchers aim to understand how well this cartilage repair method works in the long run.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients who underwent autologous chondrocyte transplantation surgery delivered on biomaterial (Hyalograft C) from 1999 to 2006 at the Rizzoli Orthopaedic Institute who met the following criteria at the time of surgery:
• • Full-thickness chondral defects (Outerbridge grade III - IV) and osteochondral defects at the femoral condyles, trochlea, patella and tibial plateau.
• • Patients aged between 14 and 60 years at the time of surgery.
• • Male and female sex.
• Exclusion Criteria:
• • Patients no longer available